150 related articles for article (PubMed ID: 8435364)
21. Treatment of advanced ovarian cancer with cisplatin, adriamycin and cyclophosphamide (PAC).
Diaz-Rubio E; Escudero M; Martin-Jimenez M; Vidart JA; Gonzalez-Larriba JL; Herraiz MA; Lopez Vega JM; Bullon F
Eur J Gynaecol Oncol; 1989; 10(6):424-32. PubMed ID: 2627975
[TBL] [Abstract][Full Text] [Related]
22. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
[TBL] [Abstract][Full Text] [Related]
23. Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.
Polyzos A; Tsavaris N; Kosmas C; Petrikos G; Giannikos L; Kalahanis N; Papadopoulos O; Christodoulou K; Giannakopoulos K; Veslemes M; Katsilambros N
J Chemother; 1999 Apr; 11(2):144-9. PubMed ID: 10326746
[TBL] [Abstract][Full Text] [Related]
24. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
Piccart MJ; Bertelsen K; James K; Cassidy J; Mangioni C; Simonsen E; Stuart G; Kaye S; Vergote I; Blom R; Grimshaw R; Atkinson RJ; Swenerton KD; Trope C; Nardi M; Kaern J; Tumolo S; Timmers P; Roy JA; Lhoas F; Lindvall B; Bacon M; Birt A; Andersen JE; Zee B; Paul J; Baron B; Pecorelli S
J Natl Cancer Inst; 2000 May; 92(9):699-708. PubMed ID: 10793106
[TBL] [Abstract][Full Text] [Related]
25. Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer.
Rothenberg ML; Ozols RF; Glatstein E; Steinberg SM; Reed E; Young RC
J Clin Oncol; 1992 May; 10(5):727-34. PubMed ID: 1569445
[TBL] [Abstract][Full Text] [Related]
26. Phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma: preliminary results.
Coeffic D; Benhammouda A; Antoine EC; Rixe O; Paraiso D; Auclerc G; Nizri D; Renody N; Grapin JP; Mularoni E; Rattini E; Soubrane C; Weil M; Mortier N; Khayat D
Semin Oncol; 1996 Dec; 23(6 Suppl 15):5-8. PubMed ID: 8996589
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity.
Lévi F; Benavides M; Chevelle C; Le Saunier F; Bailleul F; Misset JL; Regensberg C; Vannetzel JM; Reinberg A; Mathé G
J Clin Oncol; 1990 Apr; 8(4):705-14. PubMed ID: 2179481
[TBL] [Abstract][Full Text] [Related]
28. High-dose, brief duration, multiagent chemotherapy for metastatic breast cancer.
Lamar RE; Greco FA; Johnson DH; Murphy PB; Hainsworth JD
Cancer; 1994 Apr; 73(7):1842-8. PubMed ID: 8137208
[TBL] [Abstract][Full Text] [Related]
29. Carboplatin/cyclophosphamide combination chemotherapy for advanced ovarian cancer.
Teeling M; Hayes Y; Fitzmaurice B; McGing P; Carney DN
Semin Oncol; 1992 Feb; 19(1 Suppl 2):102-6. PubMed ID: 1411620
[TBL] [Abstract][Full Text] [Related]
30. High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC).
Joly F; Héron JF; Kerbrat P; Chauvergne J; Rios M; Mayer F; Chinet-Charrot P; Goupil A; Lebrun-Jezekova D; Vennin D; Lhommé C; Macé-Lesec'h J; Crouet H
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):361-8. PubMed ID: 10985895
[TBL] [Abstract][Full Text] [Related]
31. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
Kemp G; Rose P; Lurain J; Berman M; Manetta A; Roullet B; Homesley H; Belpomme D; Glick J
J Clin Oncol; 1996 Jul; 14(7):2101-12. PubMed ID: 8683243
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.
Swenerton K; Jeffrey J; Stuart G; Roy M; Krepart G; Carmichael J; Drouin P; Stanimir R; O'Connell G; MacLean G
J Clin Oncol; 1992 May; 10(5):718-26. PubMed ID: 1569444
[TBL] [Abstract][Full Text] [Related]
33. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
34. Carboplatin (CBDCA)-hexamethylmelamine (HMM)-oral etoposide (VP-16) first-line treatment of ovarian cancer patients with bulky disease: a phase II study.
Frasci G; Comella G; Comella P; Conforti S; Mastrantonio P; Zullo F; Persico G
Gynecol Oncol; 1995 Jul; 58(1):68-73. PubMed ID: 7789893
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin and cyclophosphamide in advanced ovarian carcinoma: activity and toxicity of an ambulatory regimen.
Zambetti M; Gianni L; Di Re F; Spatti G; Fontanelli R; Escobedo A; De Palo G; Bonadonna G
Am J Clin Oncol; 1990 Jun; 13(3):199-203. PubMed ID: 2161174
[TBL] [Abstract][Full Text] [Related]
36. Combined carboplatin and cisplatin. Limited prospects for dose intensification.
Waterhouse DM; Reynolds RK; Natale RB
Cancer; 1993 Jun; 71(12):4060-6. PubMed ID: 8508371
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of combination chemotherapy in advanced ovarian carcinoma with cisplatin and cyclophosphamide plus reduced glutathione as potential protective agent against cisplatin toxicity.
Locatelli MC; D'Antona A; Labianca R; Vinci M; Tedeschi M; Carcione R; Corbo A; Venturino P; Luporini G
Tumori; 1993 Feb; 79(1):37-9. PubMed ID: 8497920
[TBL] [Abstract][Full Text] [Related]
38. Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer.
Malmström H; Rasmussen S; Simonsen E
Gynecol Oncol; 1993 May; 49(2):166-71. PubMed ID: 8504983
[TBL] [Abstract][Full Text] [Related]
39. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
40. Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma.
Cocconi G; Bella M; Lottici R; Leonardi F; Ceci G; Passalacqua R; Di Blasio B; Bordi C; Biscottini B; Melpignano M; De Biasi D; Finardi C; Bacchi M
Am J Clin Oncol; 1999 Dec; 22(6):559-67. PubMed ID: 10597739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
